VVUS FDA panel meeting notes

Often times before a panel meeting (no later than 48 hours before the scheduled time), the FDA would prepare and release background material including comments on the examination of clinical trial data by a carefully chosen group of physicians. From this, a general sense of whether the drug being scrutinized would receive a solid recommendation from the medical experts for marketing approval can be extracted. Thus, working forward from the programmed meeting date of July 15, by the end of tomorrow the meeting notes should be available and the share price will undoubtedly reflect and amplify the experts' judgment. Keep alert throughout the day and check the FDA advisory calendar for any updates. Unfortunately, by the time the information becomes available to the 'general public' the stock price would have moved considerably already, so decide what you want to do FAST - whether you want to buy, sell, short the stock or trade options. VVUS' panel meeting with the FDA has been one of the most highly anticipated events in the past a year due to the unique indication (i.e. weight loss) that the drug intends to target. I am personally excited about this meeting, the outcome of which will set the tone for the upcoming assessment of another two potential weight loss medications by Arena Pharmaceuticals (ARNA) and Orexigen Therapeutics (OREX).